The people signing off.
Element MD's release decisions are reviewed by an independent six-person scientific advisory board. Their names, papers, scope of review, and 2026 conflict disclosures are public, on record, and unredacted. Any of them can stop a release. Three have, in 2026 alone.
Independent.
No advisor is a Element MD employee, contractor with delivery obligations, or shareholder. Honoraria are paid for review hours; nothing is contingent on outcome.
Binding.
Any single advisor can veto a release within their scope of review. Their report is published with the COA when they sign off.
Disclosed.
Conflict disclosures are renewed annually and published below. Recusals are logged. The 2026 declarations are linked under each name.
Replaceable.
Three-year terms, single renewal max. The board cycles. We don't get attached to advisors who never push back.
Six independent scientists.
Dr. Alina Rusev, MD, PhD
Endocrinology · Karolinska Institute · Editorial board, J. Endocrinology25 years in metabolic medicine, with primary research on GLP-1 receptor pharmacology. Reviews all weight-loss and metabolic peptide releases. Lead reviewer on Retatrutide and Tirzepatide programs.
2026 disclosure
Honoraria from Novo Nordisk educational program (declined 2024 onwards). No active grants from peptide industry. No Element MD equity.
Dr. Daniel Okeke, PhD
Analytical Chemistry · UCSF · 70+ peer-reviewed papers in mass specBuilt the LC-MS/MS protocol library used by three of the five FDA-registered peptide labs in the US. Reviews our identity and purity panels for every release lot of regulated GLP-1 analogs.
2026 disclosure
Consulting role with two unrelated diagnostic-equipment vendors ($28k total). No peptide-industry consulting. No Element MD equity.
Dr. Mei Lin, PhD
Microbiology · Former QC director, Pfizer · 18 yrs aseptic manufacturingReviews our aseptic fill SOPs, environmental monitoring data, and endotoxin / bioburden release results. Visits our fill suite quarterly and signs off on the EM trend report.
2026 disclosure
No outside peptide consulting. Faculty position (unpaid) at SUNY Buffalo School of Pharmacy. No Element MD equity.
Dr. Rajesh Mehta, MD
Sports medicine · Mayo Clinic · USOPC team physician 2014–2020Reviews any peptide we evaluate in the recovery / performance categories. His scope of review is narrowed to mechanism-of-action plausibility and safety; he does not review process chemistry.
2026 disclosure
One peer-review honorarium from a competitor's clinical-grade BPC-157 program (~$3,200, 2024). Disclosed and recused from BPC release reviews 2024.
Dr. Sara Vossen, PhD
Pharmaceutical chemistry · ETH Zürich · Author, "Peptide Drug Stability" (Wiley, 2021)Designed our long-term stability program. Reviews all stability-trend reports, shelf-life decisions, and any change to lyophilization or formulation SOPs.
2026 disclosure
Royalties from Wiley publication (peptide stability textbook, ~$8k/yr). No industry consulting. No Element MD equity.
Dr. Jordan Asher, JD, MPH
Regulatory ethics · Georgetown Law · Former staff, FDA OCBQNon-scientist seat. Reviews our customer-facing claims, label copy, and regulatory posture. Has redrafted three site-wide statements to remove implicit therapeutic claims.
2026 disclosure
No industry consulting. Pro-bono work for FDA Office of Compliance. No Element MD equity.
Every batch passes through four sets of eyes before it ships.
QC data drop
Element MD's internal lab posts the full QC packet (HPLC, LC-MS/MS, KF, endotoxin, bioburden, EM) into the advisor portal within 24 hr of completion.
Lead advisor signs
The lead advisor for the program (e.g., Dr. Rusev for Retatrutide) reads the packet, asks questions, and either signs the release form or returns it for re-test.
Second signature
A second advisor in an adjacent discipline (e.g., Dr. Okeke on identity, Dr. Lin on sterility) co-signs. Two unrelated specialties have to agree.
Report publishes
Both signatures, the COA, and any review notes are posted to the lot page on this site. Customers can read the actual review report, not a summary.
Three releases did not ship in 2026.
When the board pushes back, the lot doesn't move. Here's every veto on file this year, with the reviewer, the reason, and the resolution. We post the bad ones too.
Lot RT-2602-B Retatrutide — secondary mass-spec peak at 2872 Da inconsistent with LC-MS/MS reference. Below 0.3% but flagged as unidentified.
Lot destroyedEM trend in Fill Room 2 — three weeks of upward drift in viable counts on settle plates. Within action limits but trending toward alert.
Held · re-qualifiedMarketing copy on a stack page — phrase implied a therapeutic outcome. Required rewrite before public release. Also flagged the pre-print citation as too thin to support the claim.
Copy revised"The point of an advisory board isn't to endorse. It's to be the person who can say no, and have it stick. If a board can't kill a release, it's a marketing asset."
MD, PhD Endocrinology · Karolinska Institute
Reviews every release in the metabolic program. Has issued two release vetoes since joining the board in 2024.
Read the full charter.
The advisor charter — names, terms, conflict rules, recusal triggers, and the binding contract every advisor signs — is published in full. No NDAs, no redactions.